Pancreatitis Risk with Januvia (Sitagliptin)
Introduction to Pancreatitis Risk
- The American Diabetes Association recommends discontinuing Januvia if pancreatitis is suspected and not restarting in patients with a history of pancreatitis, due to the potential concern of pancreatitis with DPP-4 inhibitors like sitagliptin (Januvia) 1
Patient Screening and Monitoring
- Before initiating Januvia, screen for history of pancreatitis and assess for other risk factors for pancreatitis, and do not initiate in patients with a history of pancreatitis, as recommended by the American Diabetes Association 1
- Patients with severe hypertriglyceridemia (>500 mg/dL) are at increased risk for pancreatitis, and extra caution should be used when considering Januvia in these patients 2
Treatment and Discontinuation
- If pancreatitis is suspected during treatment with Januvia, discontinue Januvia immediately, perform appropriate diagnostic tests, and provide supportive care as needed, as recommended by the American Diabetes Association 1
- If pancreatitis occurs, permanently discontinue Januvia and consider alternative diabetes medications with lower or no pancreatitis risk 1
Risk Assessment
- The absolute risk of pancreatitis with sitagliptin appears to be low (approximately 0.1-0.3% in clinical studies), but potentially serious when it occurs, according to the American Diabetes Association's 2025 Standards of Care 1